NALCN Methylation as a Biomarker for Lung Cancer Metastasis
Author Information
Author(s): Eleni Thanou, Dora Lontra, Ioanna Balgouranidou, Eleni Efthimiadou, Alexandra Delipetrou, Emilia Tsaroucha, Maria Theodosiou, Vassilis Georgoulias, Athanasios Kotsakis, Evi Lianidou, Athina Markou
Primary Institution: University of Athens
Hypothesis
The methylation status of the NALCN promoter is correlated with metastatic risk in non-small cell lung cancer (NSCLC) patients.
Conclusion
NALCN promoter methylation is associated with worse disease-free intervals in NSCLC patients and may serve as a prognostic biomarker.
Supporting Evidence
- NALCN was underexpressed in 54.5% of tumor tissues.
- Hypermethylation of NALCN was detected in 66.7% of patients with recurrence.
- Kaplan–Meier analysis showed an association between NALCN hypermethylation and worse disease-free intervals.
- NALCN methylation was detected in 5.1% of early and 10.2% of advanced NSCLC cases.
Takeaway
This study found that changes in a specific gene's methylation can help predict how likely lung cancer is to spread.
Methodology
The study analyzed NALCN promoter methylation in NSCLC tissues and plasma ctDNA from patients using real-time methylation-specific PCR.
Limitations
The study's findings need validation in a larger and well-defined patient cohort.
Participant Demographics
The study included 39 early-stage and 39 advanced-stage NSCLC patients, along with 10 healthy donors.
Statistical Information
P-Value
p = 0.009 for expression differences, p = 0.017 for disease-free intervals
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website